An independent, source-linked map of systemic lupus erythematosus (SLE) researchCause candidates ·Fix attempts ·Methods & editorial policyEvidence cutoff: 2026-08-05 · research information, not medical advice
Research radar
A curated change log that separates new evidence from new interpretation, with source dates and editorial review visible.
Editorial feed
Hydroxychloroquine did not delay progression from incomplete lupus to classified SLE, overturning an earlier retrospective signal. The field now has no validated pre-disease intervention. Under-enrichment—far fewer participants progressed than assumed—means this may indict the population rather than the drug.
ContradictedA phase 1/2 basket trial reported no relapses at roughly a year of median follow-up, with protective vaccine antibodies preserved. Registrational programs are now running, one of them with drug-free remission as its primary endpoint. Still single-arm, still refractory-only, still short.
Emerging / preliminaryThe same audited evidence, restated without jargon and sorted by how strong it actually is. The layer may simplify the evidence but may not outrun it: every record resolves to the same source ledger, and the validator rejects any cause without a stated counter-case.
Citation auditedThe August batch added the monogenic causation tier, the negative and failed-approach records, and the 2025–26 trial readouts. Conference-only results were deliberately not added as sources.
Citation auditedEvery public record shows study design, clinical directness, supporting or qualifying sources, limitations, and a verification date.
Citation auditedRegistry status and enrollment are operational metadata, not results. Future changes enter a non-publishing review queue.
Registry evidenceCombination ideas now appear only as bounded research questions with testable predictions and explicit failure conditions.
CorrectedIdentifier matching, freshness checks, and research diffs flag affected records while preserving human publication authority.
Ongoing monitoring